High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine
- 23 February 1996
- journal article
- clinical trial
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 677 (1) , 141-146
- https://doi.org/10.1016/0378-4347(95)00440-8
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agentsJournal of Medicinal Chemistry, 1992
- Pioglitazone increases insulin sensitivity by activating insulin receptor kinaseDiabetes, 1992
- Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expressionEndocrinology, 1992
- Glucose Transport Deficiency in Diabetic Animals Is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone*Endocrinology, 1991
- Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid chromatography with ultraviolet (229 nm) detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1989